Simultaneous determination of clofibrate and its active metabolite clofibric acid in human plasma liquid chromatography with by reversed-phase high-performance ultraviolet absorbance detection

被引:10
作者
Du, LH [1 ]
Xu, Y [1 ]
Musson, DG [1 ]
机构
[1] Merck Res Labs, W Point, PA 19486 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2003年 / 794卷 / 02期
关键词
clofibrate; clofibric acid;
D O I
10.1016/S1570-0232(03)00500-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A reversed-phase high-performance liquid chromatographic (HPLC) using ultraviolet (UV) absorbance detection method for simultaneous determination of clofibrate (I) and its major metabolite clofibric acid (II) in human plasma has been developed to support a clinical study. I, II and internal standard (I.S., III) are isolated from human plasma by 96-well solid-phase extraction (SPE) C-18.AR plate and quantified by direct injection of the SPE eluent onto the HPLC with UV detection wavelength at 230 nm. Two chromatographic methods, isocratic and step gradient, have been validated from 1.0 to 100.0 mug/ml and successfully applied to plasma sample analysis for a clinical study. The lower limit of quantitation (LLOQ) is 1.0 mug/ml for both I and II when 500 mul plasma sample is processed. Sample collection and preparation is conducted at 5 degreesC to minimize the hydrolysis of I to II in human plasma. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:343 / 351
页数:9
相关论文
共 9 条
[1]   BILIARY LIPID-COMPOSITION DURING TREATMENT WITH DIFFERENT HYPOLIPEMIC DRUGS [J].
ANGELIN, B ;
EINARSSON, K ;
LEIJD, B .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1979, 9 (03) :185-190
[2]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR THE SIMULTANEOUS DETERMINATION OF ETHYL CLOFIBRATE AND CLOFIBRIC ACID IN PLASMA - EVALUATION OF PLASMA STABILITY OF ETHYL CLOFIBRATE POLYLACTIC NANOCAPSULES IN HUMAN AND RAT PLASMAS [J].
BARRA, J ;
TABURET, AM ;
JARDEL, A ;
FESSI, H ;
PUISIEUX, F .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 661 (01) :178-182
[3]   CLOFIBRATE THERAPY AND GALLSTONE INDUCTION [J].
BATESON, MC ;
MACLEAN, D ;
ROSS, PE ;
BOUCHIER, IAD .
AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1978, 23 (07) :623-628
[4]  
GARRETT RE, 1982, J PHARM SCI, V71, P14
[5]   GEMFIBROZIL - THE EFFECT ON BILIARY CHOLESTEROL SATURATION OF A NEW LIPID-LOWERING AGENT AND ITS COMPARISON WITH CLOFIBRATE [J].
HALL, MJ ;
NELSON, LM ;
RUSSELL, RI ;
HOWARD, AN .
ATHEROSCLEROSIS, 1981, 39 (04) :511-516
[6]  
MEFFIN PJ, 1983, J PHARMACOL EXP THER, V227, P732
[7]   BILIARY AND PLASMA-LIPIDS AND LIPID-LOWERING CHEMOTHERAPY - STUDIES WITH CLOFIBRATE, FENOFIBRATE AND ETOFIBRATE IN HEALTHY-VOLUNTEERS [J].
SCHLIERF, G ;
CHWAT, M ;
FEUERBORN, E ;
WULFINGHOF, E ;
HEUCK, CC ;
KOHLMEIER, M ;
OSTER, P ;
STIEHL, A .
ATHEROSCLEROSIS, 1980, 36 (03) :323-329
[8]   THE SIMULTANEOUS ANALYSIS OF CLOFIBRIC ACID AND PROBENECID AND THE DIRECT ANALYSIS OF CLOFIBRIC ACID GLUCURONIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
VEENENDAAL, JR ;
MEFFIN, PJ .
JOURNAL OF CHROMATOGRAPHY, 1981, 223 (01) :147-154
[9]   PROBENECID-CLOFIBRATE INTERACTION [J].
VEENENDAAL, JR ;
BROOKS, PM ;
MEFFIN, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (03) :351-358